Literature DB >> 15163259

Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs.

J Steven Lamberti1, John F Crilly, Kumar Maharaj, David Olson, Karen Wiener, Stephen Dvorin, G Oana Costea, Margaret P Bushey, Marci B Dietz.   

Abstract

BACKGROUND: Recent studies have suggested that patients receiving atypical antipsychotic drugs are at increased risk for developing diabetes mellitus. The purpose of this study is to examine the prevalence of diabetes in a group of adults with schizophrenia and other severe mental disorders receiving atypical antipsychotic drugs within a community mental health center setting.
METHOD: A retrospective chart review was conducted on 436 outpatients receiving either atypical antipsychotic or decanoate antipsychotic drugs at a community mental health center. Diagnosis of diabetes was established through the presence of documentation in the medical record. Patients with a history of diabetes prior to age 18 years were excluded. Data were gathered from April 2001 through September 2002.
RESULTS: The mean (SD) age of patients was 42.5 (10.8) years, and 57.3% were men. Patients were 61.5% white, 31.8% black, 5.3% Hispanic, and 2.3% other. Seventeen percent of patients had a positive family history of diabetes. Point prevalence of diabetes was 14.2% for the entire group. Chi-square analysis for the group revealed significant effects of age (chi(2) = 16.514, p <.001), family history of diabetes (chi(2) = 27.128, p <.001), and gender (chi(2) = 14.114, p <.001). A trend was noted toward a higher prevalence of diabetes among patients receiving atypical drugs (15.2%) compared with those receiving decanoate drugs (6.3%) (chi(2) = 2.984, p =.078).
CONCLUSION: Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs is substantially higher than that reported in the general population. Results of this study are limited by the retrospective methodology, which may underestimate actual prevalence by failing to detect undiagnosed cases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163259     DOI: 10.4088/jcp.v65n0517

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

1.  A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis.

Authors:  Christine L McKibbin; Shahrokh Golshan; Kathryn Griver; Katherine Kitchen; Thomas L Wykes
Journal:  Schizophr Res       Date:  2010-08       Impact factor: 4.939

2.  The role of antipsychotic agents in the development of diabetes mellitus.

Authors:  Samuel Dagogo-Jack
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-10-28

Review 3.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 4.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology.

Authors:  Marc De Hert; Mauro Mauri; Ken Shaw; Tilman Wetterling; Adam Doble; Agnès Giudicelli; Bruno Falissard
Journal:  Int J Methods Psychiatr Res       Date:  2010-12       Impact factor: 4.035

6.  Improving blood and ECG monitoring among patients prescribed regular antipsychotic medications.

Authors:  Parashar Pravin Ramanuj
Journal:  Ment Health Fam Med       Date:  2013-01

7.  Misclassification in assessment of diabetogenic risk using electronic health records.

Authors:  Almut G Winterstein; Paul Kubilis; Steve Bird; Rhonda M Cooper-DeHoff; Greg A Nichols; Joseph A Delaney
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-06-12       Impact factor: 2.890

8.  Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications.

Authors:  Sun H Kim; Gerald Reaven; Steven Lindley
Journal:  Int Clin Psychopharmacol       Date:  2011-01       Impact factor: 1.659

9.  Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Authors:  Jaana Suvisaari; Jonna Perälä; Samuli I Saarni; Tommi Härkänen; Sami Pirkola; Matti Joukamaa; Seppo Koskinen; Jouko Lönnqvist; Antti Reunanen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

10.  Feasibility and effectiveness of an automated telehealth intervention to improve illness self-management in people with serious psychiatric and medical disorders.

Authors:  Sarah I Pratt; Stephen J Bartels; Kim T Mueser; John A Naslund; Rosemarie Wolfe; Heather S Pixley; Louis Josephson
Journal:  Psychiatr Rehabil J       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.